Rchr
J-GLOBAL ID:202301007895729780   Update date: Jan. 30, 2024

Masuda Norikazu

マスダ ノリカズ | Masuda Norikazu
Affiliation and department:
Job title: Professor
Other affiliations (1):
Research keywords  (2): Breast Cancer ,  Clinical Trial
Research theme for competitive and other funds  (1):
  • 2012 - 2015 Study on stromal reaction and energy metabolism during breast cancer treatment
Papers (245):
  • Kobayashi Kokoro, Masuda Norikazu, Mizuno Toshiro, Miura Kayo, Tokuda Yutaka, Yoshinami Tetsuhiro, Kawaguchi Hidetoshi, Ohtani Shoichiro, Saeki Toshiaki, Toi Masakazu, et al. Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03). BREAST CANCER RESEARCH AND TREATMENT. 2023. 201. 3. 409-415
  • Yamawaki M, Murasato Y, Watanabe Y, Kinoshita Y, Okubo M, Yumoto K, Masuda N, Otake H, Aoki J, Nakazawa G, et al. Impact of coronary bifurcation angle on stent malapposition in a randomized comparison between proximal optimization technique followed by side branch dilatation and kissing balloon inflation. IJC Heart and Vasculature. 2023. 48
  • Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, Takahashi M, Futamura M, Matsumoto K, Aogi K, et al. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial). Journal for immunotherapy of cancer. 2023. 11. 9
  • Chiu Joanne, Su Fei, Joshi Mukta, Masuda Norikazu, Ishikawa Takashi, Aruga Tomoyuki, Zarate Juan Pablo, Babbar Naveen, Balbin O. Alejandro, Yap Yoon-Sim. Potential value of ctDNA monitoring in metastatic HR + /HER2-breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial. BMC MEDICINE. 2023. 21. 1. 306
  • Senkus Elzbieta, Delaloge Suzette, Domchek Susan M, Conte Pierfranco, Im Seock-Ah, Xu Binghe, Armstrong Anne, Masuda Norikazu, Fielding Anitra, Robson Mark, et al. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. INTERNATIONAL JOURNAL OF CANCER. 2023. 153. 4. 803-814
more...
Books (7):
  • 乳癌薬物療法の要点と盲点
    文光堂 2023 ISBN:9784830622649
  • 治療戦略に役立つ臨床医・病理医のための乳腺病理の見かた・考え方
    メジカルビュー社 2022 ISBN:9784758318174
  • 治療戦略に役立つ : 臨床医・病理医のための乳腺病理の見かた・考え方
    メジカルビュー社 2022 ISBN:9784758318174
  • 乳がん薬物療法副作用マネジメント
    メジカルビュー社 2021 ISBN:9784758318143
  • 乳がん薬物療法副作用マネジメント : プロのコツ
    メジカルビュー社 2017 ISBN:9784758318006
more...
Education (2):
  • 1997 - 2001 Osaka University
  • 1987 - 1993 Osaka University
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page